Aligos Therapeutics' better-than-expected earnings report, with both EPS and sales surpassing analyst estimates, is likely to positively impact investor sentiment in the short term. However, the significant year-over-year decrease in sales could raise concerns about the company's growth trajectory, potentially tempering the positive impact on the stock price.